IO Biotech (IOBT) to Release Quarterly Earnings on Tuesday

IO Biotech (NASDAQ:IOBT) will likely be announcing its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect IO Biotech to post earnings of ($0.45) per share for the quarter.

IO Biotech Price Performance

Shares of IOBT traded down $0.03 during mid-day trading on Tuesday, reaching $1.12. 36,266 shares of the company’s stock traded hands, compared to its average volume of 273,834. IO Biotech has a 12 month low of $0.66 and a 12 month high of $1.79. The stock has a market cap of $73.46 million, a P/E ratio of -0.81 and a beta of 0.09. The stock’s 50-day moving average is $0.95 and its two-hundred day moving average is $0.95.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IOBT. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of IO Biotech in a research note on Tuesday, April 1st. Piper Sandler raised shares of IO Biotech to a “strong-buy” rating in a research report on Wednesday, March 12th.

IO Biotech Company Profile

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.